Hematological malignacies
Conditions
Interventions
treatment group:none
Sponsors
The First Affiliated Hospital of Medical College of Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The subjects or their legal representatives signed the informed consent form before the start of the clinical study; 2. Men and women are not limited, and women of childbearing age have a negative pregnancy test within 14 days before starting the test drug; 3. Age 15-67 years old; 4. Patients with malignant hematological diseases who received in vivo non-T-depleted allogeneic haploidentical hematopoietic stem cell transplantation derived from peripheral blood stem cells; 5. ECOG physical fitness score 0~2 points; 6. No major organ dysfunction.
Exclusion criteria
Exclusion criteria: 1. Combined with active infection; 2. Patients diagnosed with aplastic anemia before transplantation or patients who died within 2 months after transplantation; 3. Combined with secondary tumor; 4. Severe central nervous system disease or mental illness makes it impossible to choose to enter or withdraw from clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-relapse mortality;Cumulative incidence of graft versus host disease;disease free survival; | — |
Countries
China
Contacts
Public ContactHuang He
The First Affiliated Hospital of Medical College of Zhejiang University
Outcome results
None listed